Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
Date:9/26/2007

DETROIT, Sept. 26 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd., (Amex: CPD) announced today that the US Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Methimazole Tablets USP, 5 mg and 10 mg (Methimazole).

Methimazole is indicated in the medical treatment of hyperthyroidism. Caraco's Methimazole is therapeutically equivalent to the FDA reference listed drug (RLD) listed in the Orange Book, Methimazole Tablets USP, 5 mg and 10 mg, respectively. According to IMS Data, for the twelve months ended June 2007, Methimazole had annual sales of approximately $21 million.

Daniel H. Movens, Caraco's Chief Executive Officer, said, "We are pleased to receive this approval from the FDA. This marks the third approval in the last 30 days and the sixth approval this quarter. This is in addition to the two tentative approvals granted by the FDA during the period. One of the main driver's of our growth is to continue to expand and strengthen our product portfolio. This will bring our total product selection to 41 different products represented by 86 various strengths."

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or cheaper products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward- looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
3. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
4. Deltanoid Pharmaceuticals begins phase II osteoporosis study
5. Doing the pharmaceutical tango
6. Want to squeeze U.S. pharmaceutical companies? Be careful what you ask for
7. The Coming of Biotech Generic Pharmaceuticals
8. Knowledge Management: The Key to Success for Life Sciences and Pharmaceutical Companies
9. Speaker announces business members of IT Task Force
10. Doyle announces technology tax credits for Berbee
11. Doyle announces new energy, global warming policies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 4, 2016 According to a ... Market - Global Industry Analysis, Size, Share, Growth, Trends, ... anticipated to expand at a CAGR of 17.1% from ... 2024. Metabolomics is the extensive study of ... tissues or organisms. Together, these small molecules and their ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... in biotechnology to help treat hormonal and stress related hair loss. With patent-pending ... the hearts of key opinion leaders in the medical and salon channels nationwide. ...
(Date:5/3/2016)... CA (PRWEB) , ... May 03, 2016 , ... ... Playbook™ enterprise talent development, skill-building and compliance training platform on mobile devices, ... training course: Overview of Regulatory Requirements for Medical Devices. The course is essential ...
(Date:5/3/2016)... Boston, Massachusetts (PRWEB) , ... May 03, 2016 ... ... communities will gather at Boston CEO 2016 on May 31st and June 1st ... off-the-record networking forum for leading executives in the life sciences, offering exclusive access ...
Breaking Biology Technology:
(Date:3/9/2016)... , March 9, 2016 This BCC Research ... states of the RNA Sequencing (RNA Seq) market for ... as instruments, tools and reagents, data analysis, and services. ... segments of the RNA-Sequencing market such as RNA-Sequencing tools ... the main factors affecting each segment and forecast their ...
(Date:3/9/2016)... , March 9, 2016  Crossmatch ® , ... enrollment solutions, today announced the addition of smart ... Altus multi-factor authentication platform. New contextual and ... to step-up security where it,s needed most — ... Washington, DC . --> ...
(Date:3/3/2016)...  FlexTech, a SEMI Strategic Association Partner, awarded five ... Development, Leadership in Education, and, in a category new ... year of the FLEXI Awards and the winners ... past years . Judging was done on a ... criteria, by a panel of non-affiliated, independent, industry experts. ...
Breaking Biology News(10 mins):